Panthera Biopartners, the UK’s leading Site Management Organisation (SMO) which runs commercial clinical trials for the pharmaceutical industry, has appointed Mark Egerton as Chairman.
Mark brings extensive experience in the pharmaceutical industry across the UK and the US. He is currently Chairman of Newmarket Strategy and was previously CEO of Quotient Sciences, where he oversaw significant growth and international expansion.
Commenting on his appointment, Mark said, “I am delighted to join the board of Panthera Biopartners. The management team has done an exceptional job in building the UK’s most successful SMO in only five years and is already working with ten of the top twelve pharmaceutical companies and seven of the top CROs. With the backing of LDC and BGF, Panthera will now seek to further expand its operations in the UK and Europe”.
Panthera Biopartners was founded in 2019 and has rapidly become a key partner for global pharmaceutical and biotech companies, supporting faster and more efficient patient recruitment across a growing network of dedicated clinical trial sites.
